RCKT
ROCKET PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.37
−3.71%Sep 15, 2026, 11:00 UTC
Rocket Pharmaceuticals announced alignment with the U.S. Food and Drug Administration on continued enrollment and dosing and key elements of the global pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease, including a recalibrated dose.
Source:Aug 11, 2026, 19:26 UTC
Rocket Pharmaceuticals is advancing preparations for the launch of Kresladi, a gene therapy product.
Source:Aug 11, 2026, 19:26 UTC
Rocket Pharmaceuticals reported higher earnings in the second quarter of 2026 compared to the same period last year.
Source:Aug 3, 2026, 11:00 UTC
Rocket Pharmaceuticals announced a positive clinical safety update from the initial three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease.
Source:Jun 12, 2026, 00:00 UTC
Rocket Pharmaceuticals, Inc. sold its Rare Pediatric Disease Priority Review Voucher to an unnamed large pharmaceutical company for $180 million in gross proceeds.
Source: